Leslie Shaw to Mycophenolic Acid
This is a "connection" page, showing publications Leslie Shaw has written about Mycophenolic Acid.
Connection Strength
4.258
-
Kaplan B, Gaston RS, Meier-Kriesche HU, Bloom RD, Shaw LM. Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Ther Drug Monit. 2010 Apr; 32(2):224-7.
Score: 0.326
-
van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S244-53.
Score: 0.240
-
Venkataramanan R, Shaw LM. Therapeutic monitoring of mycophenolic acid in liver transplant patients. Liver Transpl. 2004 Apr; 10(4):503-5.
Score: 0.215
-
Pawinski T, Shaw LM. Stability of mycophenolic acid in plasma samples from patients during mycophenolate mofetil therapy. Acta Pol Pharm. 2003 Mar-Apr; 60(2):121-4.
Score: 0.200
-
Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001 Aug; 23(4):305-15.
Score: 0.179
-
Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001 Feb; 34(1):17-22.
Score: 0.173
-
DeNofrio D, Loh E, Kao A, Korecka M, Pickering FW, Craig KA, Shaw LM. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000 Nov; 19(11):1071-6.
Score: 0.170
-
Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000 Jun; 40(6):624-33.
Score: 0.165
-
Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000 Feb; 22(1):14-9.
Score: 0.161
-
Korecka M, Nikolic D, van Breemen RB, Shaw LM. The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Clin Chem. 1999 Jul; 45(7):1047-50.
Score: 0.155
-
Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Brayman KL, Shaw LM. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999 Jul; 39(7):715-20.
Score: 0.155
-
Shaw LM, Korecka M, Aradhye S, Grossman R, Barker C, Naji A, Brayman KL. Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant Proc. 1998 Aug; 30(5):2234-6.
Score: 0.145
-
Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem. 1998 Jul; 31(5):317-22.
Score: 0.145
-
Shaw LM, Korecka M, van Breeman R, Nowak I, Brayman KL. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem. 1998 Jul; 31(5):323-8.
Score: 0.145
-
Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998 Apr 27; 65(8):1127-9.
Score: 0.143
-
Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998 Mar; 38(3):268-75.
Score: 0.141
-
Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit. 1997 Jun; 19(3):358-60.
Score: 0.134
-
Nowak I, Wu J, Brayman KL, Shaw LM. Is the glucuronide metabolite of MPA pharmacologically active? Transplant Proc. 1997 Feb-Mar; 29(1-2):337.
Score: 0.131
-
Shaw LM. Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. Drug Metabol Drug Interact. 1997; 14(1):33-40.
Score: 0.130
-
Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit. 1995 Dec; 17(6):685-9.
Score: 0.121
-
Shaw LM, Sollinger HW, Halloran P, Morris RE, Yatscoff RW, Ransom J, Tsina I, Keown P, Holt DW, Lieberman R, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit. 1995 Dec; 17(6):690-9.
Score: 0.121
-
Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995 Jul; 41(7):1011-7.
Score: 0.117
-
de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009 Dec; 36(6):541-64.
Score: 0.079
-
Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
Score: 0.077
-
van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009; 48(7):463-76.
Score: 0.075
-
Brandhorst G, Marquet P, Shaw LM, Liebisch G, Schmitz G, Coffing MJ, Domke I, Streit F, Luthe H, Oellerich M. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Ther Drug Monit. 2008 Aug; 30(4):428-33.
Score: 0.073
-
van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006 Apr; 28(2):145-54.
Score: 0.062
-
Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):45-9.
Score: 0.048
-
Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000 Feb; 22(1):27-30.
Score: 0.040
-
Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999 Oct; 21(10):1632-52; discussion 1631.
Score: 0.039
-
Shipkova M, Niedmann PD, Armstrong VW, Sch?tz E, Wieland E, Shaw LM, Oellerich M. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998 Jul; 44(7):1481-8.
Score: 0.036
-
Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
Score: 0.035
-
Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. Transplant Proc. 1997 Dec; 29(8):3669-70.
Score: 0.035
-
Weber M, Ketchum RJ, Sellers M, Aradhye S, Deng S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. Transplant Proc. 1997 Feb-Mar; 29(1-2):338-9.
Score: 0.033
-
Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002 Feb; 24(1):59-67.
Score: 0.012